Summit Therapeutics
Manufacturing · United Kingdom · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Rosemary Lane, Cambridge, Cambridgeshire...Phone Number
+44 1235443939Website
www.summitplc.comRevenue
<$5 MillionIndustry
About Summit Therapeutics
Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of medicinal therapies intended to resolve serious unmet medical needs for cancer patients. The company is developing ivonescimab, a novel investigational bispecific antibody that combines PD-1 blockade with VEGF blocking to provide immunotherapy and anti-angiogenesis effects. Through a partnership with Akeso, Inc., Summit is conducting Phase 3 clinical trials for ivonescimab, specifically targeting non-small cell lung cancer and other solid tumors. Its operations serve oncology patients, physicians, and caregivers across license territories including the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa.Explore more
SIC Code 28,283NAICS Code 32,325Show moreSummit Therapeutics Org Chart
Compare Similar Companies to Summit Therapeutics
Compare insights from companies similar to Summit Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Summit Therapeutics
<$5M
1-10
Private
-
2004
NG
Nrupali GandhiSenior Director, Pharmacovigilance Operations
Summit Therapeutics Tech Stack
A closer look at the technologies used by Summit Therapeutics
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Summit Therapeutics
Sign Up For FreeTo access detailed company insights
Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of medicinal therapies intended to resolve serious unmet medical needs for cancer patients. The company is developing ivonescimab, a novel investigational bispecific antibody that combines PD-1 blockade with VEGF blocking to... Read More